Nucleic Acid Therapeutics CDMO Market Booming: A $4.69 Billion Opportunity by 2030 (Highlights projected market size)

Nucleic Acid Therapeutics CDMO Market worth $4.69 Bn by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global Nucleic Acid Therapeutics CDMO Market By Technology (Column-Based Method and Microarray-Based Method), Products (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, and Other Services), End-users (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories) Chemical Synthesis (Solid-Phase Oligonucleotide Synthesis, Liquid-Phase Oligonucleotide Synthesis) - By Trends, Industry Competition Analysis, Revenue and Forecast Till 2030"

According to the latest research by InsightAce Analytic, the global nucleic acid therapeutics CDMO market size valued at US$ 1.93 billion in 2021 and it is expected to reach US$ 4.69 billion in 2030, recording a promising CAGR of 10.7% during the period of 2022-2030. By region,

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1348

Treatments involving nucleic acids are frequently employed to address a range of hereditary illnesses. Applications of nucleic acid treatments are becoming more and more necessary due to the increased frequency of hereditary and chronic disorders. Deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or other related chemical substances are the foundation for nucleic acid treatments.

To increase their investment in the production of nucleic acid-based medicines, the manufacturers in this sector are entering into new alliances, agreements, partnerships, collaborations, mergers, and business expansions with the contract development and manufacturing organization (CDMO). One example is the acquisition of all allocated and existing shares of GeneDesign, Inc., a significant Japanese contract development and manufacturing organization (CDMO1) for nucleic acid pharmaceuticals, by Ajinomoto Co., Inc. and OmniChem N.V. ("OmniChem") in December 2016.

This acquisition will accelerate the company's growth in CDMOs for nucleic acid medications. The market is poised for growth in the forecast years , driven by factors such as the increasing demand for novel therapies based on mRNA, the upward trajectory of healthcare costs, the potential for manufacturing cost reduction at CDMOs, the rise in the approval of nucleic acid drugs, and the rapid adoption of cutting-edge nucleic acid technologies for disease diagnosis and treatment .

However, challenges such as supply chain and targeted delivery issues, maintaining efficacy and limiting off-target toxicity, and a lack of experience in nucleic acid production may impede the market's expansion. Due to rising R&D efforts, the entry of new competitors, and the strong demand for nucleic acid therapeutics-primarily due to the COVID-19 pandemic and improved reimbursement practices in the area-North America is the region with the quickest rate of growth. Conversely, the Asia Pacific nucleic acid therapies CDMO market is anticipated to rise faster due to the rising incidence of genetic disorders, expanding biopharmaceutical companies, and improvements in medical technologies.

Major Key Players in the Nucleic Acid Therapeutics CDMO Market:

Agilent Technologies, Inc.
Ajinomoto Co. Inc.
Bachem Holding AG.
Biospring GmbH
Corden Pharma International
Danaher Corporation
Guangzhou Ruibo Biotechnology Co., Ltd.
KNC Laboratories Co., Ltd.
LGC Limited
Merck KGaA
Nippon Shokubai Co., Ltd.
Nitto Denko Avecia Inc
QIAGEN N.V.
S.T. Pharm Co Ltd
Sumitomo Chemical Co., Ltd.
Syngene International Limited
Thermo Fisher Scientific Inc.
Wuxi AppTec
Yamasa Corporation
Laboratorios Farmacéuticos Rovi, S.A.
Sartorius AG (BIA Separations)
AGC Biologics
FUJIFILM Diosynth Biotechnologies
Hanmi Pharmaceutical
Arranta Bio (Recipharm)
ST Pharm
BioCina Pty Ltd.
Curia Global, Inc.
Other Prominent Players

Key Industry Developments:

• In June 2022, Merck agreed with Agilent Technologies to develop Process Analytical Technologies (PAT). Merck and Agilent Technologies are filling a void in the downstream PAT market through this partnership. Merck expands real-time monitoring and automated process control of key process parameters (CPPs) and critical quality attributes (CQAs) to downstream processing through the combination of its bioprocess portfolio with Agilent Technologies' sophisticated analytical technologies.

• In June 2022, CordenPharma expanded its xRNA capabilities at its Caponago, Italy, plant for sterile injectables. The business claims to have invested over €10 million in a new formulation, research, and manufacturing areas for Lipid Nanoparticles (LNP). The expansion will help clients go from pre-clinical to clinical development of xRNA-based treatments (mRNA, siRNA, saRNA, microRNA, etc.), accelerating the delivery of their new medicinal solutions into clinical stages and beyond.

• In Feb 2022, Recipharm has acquired Arranta Bio. The acquisition is a cornerstone of Recipharm's strategy to provide scientifically differentiated contract development and manufacturing services for ATMPs to innovative drug developers in the Biologics market. It builds on the capabilities acquired through the recently announced GenIbet transaction and the acquisition of Vibalogics.

• In June 2021, Danaher Corporation announced that it would add protein production, plasmid DNA, and mRNA services to its bulging life sciences portfolio by acquiring Aldevron. Through the acquisition, Danaher adds contract manufacturing services.

• In August 2020, Agilent Technologies Inc. announced it would extend its advanced production facility in Frederick, Colorado, that develops and produces "oligos," which are short DNA and RNA molecules used to make nucleic acid-based therapeutics. Oligos hold the potential to be used in inventing treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases, and other conditions. The expansion has increased the current capacity for manufacturing therapeutic oligos at the Frederick site.

Interested in Buying @ https://www.insightaceanalytic.com/enquiry-before-buying/1348

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Technology

• Column-Based Method
• Microarray-Based Method

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Products

• Standard Nucleic Acid
• Micro-Scale Nucleic Acid
• Large-Scale Nucleic Acid
• Custom Nucleic Acid
• Modified Nucleic Acid
• Primers
• Probes
• Other Nucleic Acid
• Other Services

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Chemical Synthesis

• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on End-Users

• Pharmaceutical Companies
• Academic Research Institute
• Diagnostic Laboratories

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2030 based on Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030

• U.S.
• Canada

Europe Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030

• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030

• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Nucleic Acid Therapeutics CDMO market revenue (US$ Million) by Country, 2022 to 2030

• GCC Countries
• South Africa
• Rest of Middle East & Africa

For More Information @ https://www.insightaceanalytic.com/customisation/1348

Why should buy this report:

 To receive a comprehensive analysis of the prospects for global Nucleic Acid Therapeutics CDMO market
 To receive industry overview and future trends of global Nucleic Acid Therapeutics CDMO market
 To analyse the Nucleic Acid Therapeutics CDMO market drivers and challenges
 To get information on Nucleic Acid Therapeutics CDMO market size value (US$ Mn) forecast till 2030
 To get detailed information on major Investments, Mergers & Acquisition in global Nucleic Acid Therapeutics CDMO market industry

Other Related Reports Published by InsightAce Analytic:

Global mRNA Synthesis and Manufacturing Services Market

Live Biotherapeutic Products And Microbiome Contract Manufacturing Market

Oligonucleotide Synthesis, Modification, and Purification Services Market

Global Peptide CDMO (Pharmaceutical) Market

Global Cell Therapy Packaging Products and Services Market

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 551 226 6109
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.